HENLIUS HLX22 and HLX87 clinical study completes first patient dosing
HENLIUS (02696.HK) announced that the first patient has been dosed in the Phase 2/3 clinical study of HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) in combination with HLX87 (targeted HER2 antibody-drug conjugate) as a first-line treatment for patients with HER2-positive recurrent or metastatic breast cancer in China.
HLX22 is a novel targeted HER2 monoclonal antibody licensed in by the company and subsequently developed independently, with potential indications including solid tumors such as gastric cancer and breast cancer
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments